Home Cart Sign in  
Chemical Structure| 1354707-41-7 Chemical Structure| 1354707-41-7

Structure of Mitochonic acid 5
CAS No.: 1354707-41-7

Chemical Structure| 1354707-41-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mitochonic acid 5 binds mitochondria and ameliorates renal tubular and cardiac myocyte damage. Mitochonic acid 5 modulates mitochondrial ATP synthesis.

Synonyms: MA-5

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mitochonic acid 5

CAS No. :1354707-41-7
Formula : C18H13F2NO3
M.W : 329.30
SMILES Code : O=C(O)C(CC(C1=CC=C(F)C=C1F)=O)C2=CNC3=C2C=CC=C3
Synonyms :
MA-5
MDL No. :MFCD31657404
InChI Key :BOKQALWNGNLTOC-UHFFFAOYSA-N
Pubchem ID :76070959

Safety of Mitochonic acid 5

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human skin fibroblasts 0.1 to 30 μM 72 hours MA-5 exhibited a cell-protective effect in 24/25 cases of mitochondrial disease fibroblasts, significantly reducing BSO-induced cell death and LDH level elevation. PMC5478234
Mouse microglial BV-2 cells 5 μM 12 hours MA-5 improved the survival of lipopolysaccharide-exposed cells, decreased the activity of caspase-3 associated with apoptosis, reduced the number of TUNEL-positive cells, and increased ATP levels in cells. MA-5 also decreased the open state of the mitochondrial permeability transition pore, reduced calcium overload and diffusion of Smac. Furthermore, MA-5 decreased the expression of apoptosis-related proteins and increased the levels of anti-apoptotic proteins, mitochondria-related proteins, and autophagy-related proteins. PMC8328753
Human fibroblasts 10 μM MA-5 increases cellular ATP levels, reduces mitochondrial reactive oxygen species (ROS) production, and protects cells with mitochondrial dysfunction from death PMC9455831
Mouse microglial BV-2 cells 0–10μM 12 hours MA-5 reduced TNFα-induced apoptosis via upregulation of Bnip3-related mitophagy, improving mitochondrial function. PMC5887257
Fibroblasts from MELAS patient 10 μM 3 hours MA-5 significantly increased ATP levels in fibroblasts from MELAS patients. PMC5478234
Fibroblasts from Leigh syndrome patient 10 μM 3 hours MA-5 significantly increased ATP levels in fibroblasts from Leigh syndrome patients. PMC5478234
Human OA chondrocytes 10 μM 24 hours MA-5 inhibits IL-1β-induced oxidative stress and protects chondrocytes by upregulating the SIRT3/Parkin-related autophagy signaling pathway PMC9207248
Hep3B cells 3 and 10 µM MA-5 significantly increased intracellular ATP levels PMC10394014
Ram sperm 0, 0.1, 1, 10, and 100 nM 48 hours To evaluate the effect of MA-5 on ram sperm quality, results showed that 10 nM MA-5 significantly improved sperm motility, membrane integrity, and acrosomal integrity. PMC10854625
Cardiomyocytes 5 μM 12 hours MA-5 administration increased cell viability and repressed apoptosis in H2O2-treated cardiomyocytes. PMC10757297

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mitomouse (mouse model with mitochondrial DNA deletion mutation) Mitochondrial disease model Oral 50 mg/kg body weight/day Once daily for 30 days MA-5 significantly reduced serum GDF-15 levels in Mitomouse, indicating its therapeutic effect in the mitochondrial disease model. PMC5478234

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.18mL

3.04mL

1.52mL

30.37mL

6.07mL

3.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories